IMC Logo.jpg
Immuron CEO to Present at RedChip Global Online Growth Conference
23. April 2018 18:57 ET | Immuron Limited
MELBOURNE, Australia, April 23, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), Australian microbiome biopharmaceutical company focused on developing and commercialising orally...
IMC Logo.jpg
Immuron Progresses Discussions with Institutional Funds
13. März 2018 09:30 ET | Immuron Limited
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally...
IMC Logo.jpg
Immuron to Receive $2.16M R&D Tax Concession Refund
24. Januar 2018 09:30 ET | Immuron Limited
Melbourne, Australia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to announce that under the Australian Government’s Research and Development...
IMC Logo.jpg
CEO to Present on US Investor TV Show and at Biotech Conference
10. Januar 2018 09:00 ET | Immuron Limited
MELBOURNE, Australia, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) is pleased to advise investors that CEO Dr Jerry Kanellos, was interviewed on The...
IMC Logo.jpg
Immuron to Present at RedChip’s Global Online Growth Conference
06. Dezember 2017 09:04 ET | Immuron Limited
MELBOURNE, Australia, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to advise investors that CEO Dr Jerry Kanellos is scheduled to present at...
IMC Logo.jpg
Immuron Successfully Completes NASH Phase II Clinical Study Milestone
09. November 2017 09:00 ET | Immuron Limited
MELBOURNE, Australia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercialising oral...
IMC Logo.jpg
Immuron Commences US Non-Deal Institutional Investor Roadshow
15. August 2017 09:15 ET | Immuron Limited
MELBOURNE, Australia, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is pleased to release to shareholders and investors...